دورية أكاديمية
أعرض في EDS

The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.

التفاصيل البيبلوغرافية
العنوان: The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.
المؤلفون: Chiu HI; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan., Wu SB; Biomedical Commercialization Center, Taipei Medical University, Taipei 110, Taiwan., Tsai CC; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 14; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 14.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Graves Ophthalmopathy*/genetics , Graves Ophthalmopathy*/metabolism , Graves Disease*/metabolism, Humans ; Orbit/metabolism ; Extracellular Matrix Proteins/genetics ; Extracellular Matrix Proteins/metabolism ; Fibroblasts/metabolism ; Fibrosis
مستخلص: Graves' ophthalmopathy (GO), or thyroid eye disease (TED), is the most frequent extrathyroidal manifestation of Graves' disease (GD). Inflammation and subsequent aberrant tissue remodeling with fibrosis are important pathogenesis. There are many proposed mechanisms and molecular pathways contributing to tissue remodeling and fibrosis in GO, including adipogenesis, fibroblast proliferation and myofibroblasts differentiation, oxidative stress, endoplasmic reticulum (ER) stress, hyaluronan (HA) and glycosaminoglycans (GAGs) accumulation in the extracellular matrix (ECM) and new concepts of epigenetics modification, such as histone modification, DNA methylation, non-coding RNAs, and gut microbiome. This review summarizes the current understanding of ECM proteins and associated tissue remodeling in the pathogenesis and potential mediators for the treatment of GO.
References: Front Immunol. 2022 Aug 23;13:952954. (PMID: 36081502)
Sci Rep. 2021 Oct 13;11(1):20305. (PMID: 34645831)
Exp Eye Res. 2020 Jul;196:108036. (PMID: 32376473)
Cureus. 2019 Dec 22;11(12):e6443. (PMID: 31998571)
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3061-6. (PMID: 20053983)
J Clin Endocrinol Metab. 2012 Mar;97(3):E400-8. (PMID: 22238384)
Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. (PMID: 33865501)
Lancet. 2012 Mar 31;379(9822):1256-68. (PMID: 22381456)
J Autoimmun. 2016 Feb;67:46-56. (PMID: 26459776)
J Transl Med. 2023 Jun 18;21(1):396. (PMID: 37331977)
Endocr J. 2014;61(11):1087-92. (PMID: 25100151)
Br J Ophthalmol. 2017 May;101(5):676-680. (PMID: 27543288)
Eur Thyroid J. 2018 Aug;7(4):167-186. (PMID: 30283735)
Eur Thyroid J. 2012 Jul;1(2):80-7. (PMID: 24783001)
Trends Cell Biol. 2017 Sep;27(9):658-672. (PMID: 28552280)
J Clin Endocrinol Metab. 2020 Nov 1;105(11):. (PMID: 32785703)
N Engl J Med. 2011 May 19;364(20):1920-31. (PMID: 21591944)
J Biol Chem. 2009 Sep 25;284(39):26447-55. (PMID: 19633293)
J Clin Endocrinol Metab. 1997 Jun;82(6):1999-2002. (PMID: 9177420)
J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. (PMID: 25494967)
Int J Mol Sci. 2021 Mar 14;22(6):. (PMID: 33799469)
Exp Eye Res. 2013 Feb;107:65-73. (PMID: 23219871)
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):908-13. (PMID: 26943153)
Eye (Lond). 2010 Sep;24(9):1520-5. (PMID: 20300129)
Biomolecules. 2021 Sep 29;11(10):. (PMID: 34680057)
Clin Endocrinol (Oxf). 2011 Jan;74(1):118-24. (PMID: 21044110)
J Clin Endocrinol Metab. 2016 Dec;101(12):4834-4842. (PMID: 27610652)
Thyroid. 2008 Sep;18(9):959-65. (PMID: 18752427)
Molecules. 2022 Dec 20;28(1):. (PMID: 36615214)
Front Endocrinol (Lausanne). 2020 Dec 14;11:608733. (PMID: 33381085)
Front Endocrinol (Lausanne). 2022 Nov 18;13:1001349. (PMID: 36465658)
Signal Transduct Target Ther. 2023 Mar 2;8(1):98. (PMID: 36864020)
J Clin Endocrinol Metab. 1998 Jan;83(1):121-4. (PMID: 9435427)
Hormones (Athens). 2020 Mar;19(1):31-39. (PMID: 31721133)
Ophthalmology. 1999 Mar;106(3):564-9. (PMID: 10080215)
J Clin Endocrinol Metab. 2007 Jan;92(1):59-64. (PMID: 17047020)
Horm Metab Res. 1998 Aug;30(8):496-9. (PMID: 9761378)
J Clin Endocrinol Metab. 2015 Feb;100(2):432-41. (PMID: 25343233)
N Engl J Med. 2020 Jan 23;382(4):341-352. (PMID: 31971679)
J Clin Endocrinol Metab. 2004 Feb;89(2):930-5. (PMID: 14764816)
Ophthalmic Plast Reconstr Surg. 2020 Mar/Apr;36(2):172-177. (PMID: 31789788)
Acta Endocrinol (Copenh). 1993 Oct;129(4):322-7. (PMID: 8237250)
Nutr J. 2015 Feb 18;14:18. (PMID: 25880386)
Semin Cell Dev Biol. 2020 May;101:115-122. (PMID: 31883994)
PLoS One. 2019 Aug 15;14(8):e0221077. (PMID: 31415657)
J Mol Endocrinol. 2021 May 11;66(4):313-323. (PMID: 33870911)
Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):608-19. (PMID: 18600514)
Front Endocrinol (Lausanne). 2021 Jan 26;11:608428. (PMID: 33574798)
J Biomed Sci. 2022 Sep 2;29(1):63. (PMID: 36050716)
J Biol Chem. 2010 May 21;285(21):15794-804. (PMID: 20308056)
Invest Ophthalmol Vis Sci. 2014 Apr 09;55(4):2276-83. (PMID: 24627146)
Invest Ophthalmol Vis Sci. 2021 Jan 4;62(1):29. (PMID: 33507228)
Microbiome. 2021 Feb 16;9(1):45. (PMID: 33593429)
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7571-7. (PMID: 25550793)
Exp Mol Med. 2020 Feb;52(2):204-212. (PMID: 32071378)
Genomics. 2021 Jan;113(1 Pt 2):440-449. (PMID: 32919017)
Thyroid. 2021 Oct;31(10):1566-1576. (PMID: 34235979)
Oxid Med Cell Longev. 2016;2016:4676289. (PMID: 27340508)
Cochrane Database Syst Rev. 2015 Nov 25;(11):CD010576. (PMID: 26606533)
J Curr Ophthalmol. 2022 Apr 16;34(1):16-24. (PMID: 35620378)
Respir Res. 2016 Mar 04;17:23. (PMID: 26944412)
Arch Ophthalmol. 2007 Dec;125(12):1652-6. (PMID: 18071117)
Nat Rev Endocrinol. 2020 Feb;16(2):104-116. (PMID: 31889140)
Microbiome. 2018 May 25;6(1):97. (PMID: 29801507)
Exp Eye Res. 2013 Aug;113:1-8. (PMID: 23664858)
Am J Ophthalmol. 2000 May;129(5):618-22. (PMID: 10844053)
Noncoding RNA. 2019 Mar 12;5(1):. (PMID: 30871125)
Nat Rev Genet. 2009 Jan;10(1):32-42. (PMID: 19065135)
N Engl J Med. 2010 Feb 25;362(8):726-38. (PMID: 20181974)
Br J Ophthalmol. 1949 Dec;33(12):769-73. (PMID: 15408010)
J Endocrinol Invest. 2009 Sep;32(8):641-6. (PMID: 19942821)
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):120-7. (PMID: 8300338)
J Exp Med. 2020 Feb 13;217(3):e20190103. (PMID: 32997468)
Lancet. 2000 Jul 15;356(9225):233-41. (PMID: 10963212)
Med Sci Monit. 2014 Apr 18;20:639-43. (PMID: 24743332)
Br J Ophthalmol. 2018 Mar;102(3):407-414. (PMID: 29101123)
Am J Ophthalmol. 2022 Aug;240:1-13. (PMID: 35227694)
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3913-21. (PMID: 16249464)
Thyroid. 2016 Oct;26(10):1343-1421. (PMID: 27521067)
J Clin Endocrinol Metab. 2021 Oct 21;106(11):3213-3227. (PMID: 34272941)
J Clin Endocrinol Metab. 2012 Feb;97(2):653-62. (PMID: 22162480)
Indian J Surg. 2017 Dec;79(6):521-526. (PMID: 29217903)
Am J Respir Crit Care Med. 2008 Jan 1;177(1):56-65. (PMID: 17916809)
Nature. 2013 Mar 21;495(7441):384-8. (PMID: 23446346)
Clin Endocrinol (Oxf). 2003 Sep;59(3):321-7. (PMID: 12919155)
Mol Vis. 2011;17:2782-8. (PMID: 22065933)
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4336-4345. (PMID: 31622470)
Biomedicines. 2021 Dec 10;9(12):. (PMID: 34944687)
Eur Thyroid J. 2020 Dec;9(Suppl 1):40-50. (PMID: 33511084)
Thyroid. 2001 Oct;11(10):929-34. (PMID: 11716039)
Am J Physiol Cell Physiol. 2010 Sep;299(3):C672-81. (PMID: 20554910)
Front Endocrinol (Lausanne). 2022 Jan 05;12:788535. (PMID: 35069441)
PLoS One. 2015 Nov 24;10(11):e0143514. (PMID: 26599235)
Exp Eye Res. 1997 Aug;65(2):311-6. (PMID: 9268599)
Sci Rep. 2018 May 8;8(1):7276. (PMID: 29739987)
Clin Biochem. 2005 Jan;38(1):13-8. (PMID: 15607311)
Clin Exp Immunol. 2008 Nov;154(2):209-15. (PMID: 18778364)
Endocr Rev. 1989 Aug;10(3):366-91. (PMID: 2673756)
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302. (PMID: 22632366)
Am J Pathol. 2003 Oct;163(4):1291-300. (PMID: 14507638)
J Clin Endocrinol Metab. 2012 Jun;97(6):E944-53. (PMID: 22438231)
Int J Mol Sci. 2018 Aug 20;19(8):. (PMID: 30127261)
Matrix Biol. 2015 Sep;47:44-53. (PMID: 25960419)
Eur J Ophthalmol. 2004 Jul - Aug 2004;14(4):277-283. (PMID: 28221442)
Invest Ophthalmol Vis Sci. 2014 Oct 23;55(11):7441-50. (PMID: 25342622)
معلومات مُعتمدة: 112-2314-B-075-003-MY2 National Taiwan University of Science and Technology; V113C-021 Taipei Veterans General Hospital
فهرسة مساهمة: Keywords: Graves’ ophthalmopathy (GO); Graves’ orbital fibroblasts; endoplasmic reticulum (ER); epigenetics; oxidative stress; transforming growth factor-β1 (TGF-β1)
المشرفين على المادة: 0 (Extracellular Matrix Proteins)
تواريخ الأحداث: Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10970309
DOI: 10.3390/ijms25063288
PMID: 38542262
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25063288